Hepatic angiosarcoma may have fair survival nowadays

Neng Chyan Huang, Yau-Chang Kuo, Jui Chin Chiang, Shih Yuan Hung, Huay Min Wang, Yao Min Hung, Yun Te Chang, Shue Ren Wann, Hong Tai Chang, Jyh Seng Wang, Sheng Yow Ho, How-Ran Guo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hepatic angiosarcoma (HAS) is rare but often fatal. A review of literature in 1979 found that only 3% of the 70 patients lived for more than 2 years, but the survival might have been improved over the years. We conducted a retrospective study and reviewed the medical records of patients who visited a teaching hospital in Taiwan from January 2000 to August 2010 and had pathological proof of HAS. In addition, we conducted a review of literature and compared those who survived for 2 years or more to those who did not. Of the 3503 patients with primary liver cancer we identified, 9 had HAS, of whom 3 (33.3%) survived for 2 years or more. One survived for 24 months without surgical resection, and the other two received surgery with postoperative chemotherapy and were still alive 32 and 37 months later, respectively. Through reviewing literature, we identified 3 more patients in Taiwan who had survived for 2 years or more. One survived for 42 months without surgical resection, the other two received segmentectomy with postoperative chemotherapy or radiotherapy. We also identified 8 such cases outside Taiwan, including 1 who received chemotherapy without surgery and survived for 53 months. None of the differences in the clinical characteristics between those who had and had not survived for 2 years or more reached statistical significance. In conclusion, we believe the combination of surgery and adjuvant chemotherapy may be able to achieve long-term survival in some HAS patients nowadays, and it is even possible to achieve fair survival using chemotherapy alone.

Original languageEnglish
Article number816
JournalMedicine (United States)
Volume94
Issue number19
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Hemangiosarcoma
Taiwan
Survival
Liver
Drug Therapy
Segmental Mastectomy
Adjuvant Chemotherapy
Liver Neoplasms
Combination Drug Therapy
Teaching Hospitals
Medical Records
Radiotherapy
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Huang, Neng Chyan ; Kuo, Yau-Chang ; Chiang, Jui Chin ; Hung, Shih Yuan ; Wang, Huay Min ; Hung, Yao Min ; Chang, Yun Te ; Wann, Shue Ren ; Chang, Hong Tai ; Wang, Jyh Seng ; Ho, Sheng Yow ; Guo, How-Ran. / Hepatic angiosarcoma may have fair survival nowadays. In: Medicine (United States). 2015 ; Vol. 94, No. 19.
@article{d9f82608eb694e41a14def535bd3f752,
title = "Hepatic angiosarcoma may have fair survival nowadays",
abstract = "Hepatic angiosarcoma (HAS) is rare but often fatal. A review of literature in 1979 found that only 3{\%} of the 70 patients lived for more than 2 years, but the survival might have been improved over the years. We conducted a retrospective study and reviewed the medical records of patients who visited a teaching hospital in Taiwan from January 2000 to August 2010 and had pathological proof of HAS. In addition, we conducted a review of literature and compared those who survived for 2 years or more to those who did not. Of the 3503 patients with primary liver cancer we identified, 9 had HAS, of whom 3 (33.3{\%}) survived for 2 years or more. One survived for 24 months without surgical resection, and the other two received surgery with postoperative chemotherapy and were still alive 32 and 37 months later, respectively. Through reviewing literature, we identified 3 more patients in Taiwan who had survived for 2 years or more. One survived for 42 months without surgical resection, the other two received segmentectomy with postoperative chemotherapy or radiotherapy. We also identified 8 such cases outside Taiwan, including 1 who received chemotherapy without surgery and survived for 53 months. None of the differences in the clinical characteristics between those who had and had not survived for 2 years or more reached statistical significance. In conclusion, we believe the combination of surgery and adjuvant chemotherapy may be able to achieve long-term survival in some HAS patients nowadays, and it is even possible to achieve fair survival using chemotherapy alone.",
author = "Huang, {Neng Chyan} and Yau-Chang Kuo and Chiang, {Jui Chin} and Hung, {Shih Yuan} and Wang, {Huay Min} and Hung, {Yao Min} and Chang, {Yun Te} and Wann, {Shue Ren} and Chang, {Hong Tai} and Wang, {Jyh Seng} and Ho, {Sheng Yow} and How-Ran Guo",
year = "2015",
month = "5",
day = "1",
doi = "10.1097/MD.0000000000000816",
language = "English",
volume = "94",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

Huang, NC, Kuo, Y-C, Chiang, JC, Hung, SY, Wang, HM, Hung, YM, Chang, YT, Wann, SR, Chang, HT, Wang, JS, Ho, SY & Guo, H-R 2015, 'Hepatic angiosarcoma may have fair survival nowadays', Medicine (United States), vol. 94, no. 19, 816. https://doi.org/10.1097/MD.0000000000000816

Hepatic angiosarcoma may have fair survival nowadays. / Huang, Neng Chyan; Kuo, Yau-Chang; Chiang, Jui Chin; Hung, Shih Yuan; Wang, Huay Min; Hung, Yao Min; Chang, Yun Te; Wann, Shue Ren; Chang, Hong Tai; Wang, Jyh Seng; Ho, Sheng Yow; Guo, How-Ran.

In: Medicine (United States), Vol. 94, No. 19, 816, 01.05.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatic angiosarcoma may have fair survival nowadays

AU - Huang, Neng Chyan

AU - Kuo, Yau-Chang

AU - Chiang, Jui Chin

AU - Hung, Shih Yuan

AU - Wang, Huay Min

AU - Hung, Yao Min

AU - Chang, Yun Te

AU - Wann, Shue Ren

AU - Chang, Hong Tai

AU - Wang, Jyh Seng

AU - Ho, Sheng Yow

AU - Guo, How-Ran

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Hepatic angiosarcoma (HAS) is rare but often fatal. A review of literature in 1979 found that only 3% of the 70 patients lived for more than 2 years, but the survival might have been improved over the years. We conducted a retrospective study and reviewed the medical records of patients who visited a teaching hospital in Taiwan from January 2000 to August 2010 and had pathological proof of HAS. In addition, we conducted a review of literature and compared those who survived for 2 years or more to those who did not. Of the 3503 patients with primary liver cancer we identified, 9 had HAS, of whom 3 (33.3%) survived for 2 years or more. One survived for 24 months without surgical resection, and the other two received surgery with postoperative chemotherapy and were still alive 32 and 37 months later, respectively. Through reviewing literature, we identified 3 more patients in Taiwan who had survived for 2 years or more. One survived for 42 months without surgical resection, the other two received segmentectomy with postoperative chemotherapy or radiotherapy. We also identified 8 such cases outside Taiwan, including 1 who received chemotherapy without surgery and survived for 53 months. None of the differences in the clinical characteristics between those who had and had not survived for 2 years or more reached statistical significance. In conclusion, we believe the combination of surgery and adjuvant chemotherapy may be able to achieve long-term survival in some HAS patients nowadays, and it is even possible to achieve fair survival using chemotherapy alone.

AB - Hepatic angiosarcoma (HAS) is rare but often fatal. A review of literature in 1979 found that only 3% of the 70 patients lived for more than 2 years, but the survival might have been improved over the years. We conducted a retrospective study and reviewed the medical records of patients who visited a teaching hospital in Taiwan from January 2000 to August 2010 and had pathological proof of HAS. In addition, we conducted a review of literature and compared those who survived for 2 years or more to those who did not. Of the 3503 patients with primary liver cancer we identified, 9 had HAS, of whom 3 (33.3%) survived for 2 years or more. One survived for 24 months without surgical resection, and the other two received surgery with postoperative chemotherapy and were still alive 32 and 37 months later, respectively. Through reviewing literature, we identified 3 more patients in Taiwan who had survived for 2 years or more. One survived for 42 months without surgical resection, the other two received segmentectomy with postoperative chemotherapy or radiotherapy. We also identified 8 such cases outside Taiwan, including 1 who received chemotherapy without surgery and survived for 53 months. None of the differences in the clinical characteristics between those who had and had not survived for 2 years or more reached statistical significance. In conclusion, we believe the combination of surgery and adjuvant chemotherapy may be able to achieve long-term survival in some HAS patients nowadays, and it is even possible to achieve fair survival using chemotherapy alone.

UR - http://www.scopus.com/inward/record.url?scp=84938858443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938858443&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000000816

DO - 10.1097/MD.0000000000000816

M3 - Article

C2 - 25984668

AN - SCOPUS:84938858443

VL - 94

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 19

M1 - 816

ER -